2'-deoxycoformycin (DCF) and 9-beta-D-arabinofuranosyladenine (Ara-A) in the treatment of refractory acute myelocytic leukemia.
The combination of 2'-deoxycoformycin (DCF), a potent adenosine deaminase (ADA) inhibitor, and 9-beta-D-arabinofuranosyladenine (Ara-A) was used in a patient with acute nonlymphocytic leukemia refractory to all conventional modes of therapy. DCF was given by periodic iv injections to ablate ADA activity. Ara-A was given by continuous iv infusion at an initial dose of 1.5 mg/kg/day, with progressive increases to 6 mg/kg/day. With adequate ADA suppression (less than 2 x 10(-2) mumols of inosine/hr/10(6)h cells), the Ara-A decreased the absolute peripheral blood myeloblast count from 36,332 to 780/microliter. The patient experienced no renal, hepatic, or neurologic complications during therapy.
D000243:Adenosine Deaminase / Q000097:blood; D000328:Adult; D003070:Coformycin / Q000008:administration & dosage* / Q000031:analogs & derivatives; D003854:Deoxyribonucleotides / Q000097:blood; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000378:metabolism; D008297:Male; D009705:Nucleosides / Q000378:metabolism; D015649:Pentostatin; D012263:Ribonucleosides / Q000008:administration & dosage*; D012265:Ribonucleotides / Q000097:blood; D014740:Vidarabine / Q000008:administration & dosage*
D003854:Deoxyribonucleotides; D009705:Nucleosides; D012263:Ribonucleosides; D012265:Ribonucleotides; D003070:Coformycin; D015649:Pentostatin; D000243:Adenosine Deaminase; D014740:Vidarabine